scholarly journals Lung function in infants and young children with chronic lung disease of infancy: The next steps?

2006 ◽  
Vol 42 (1) ◽  
pp. 3-9 ◽  
Author(s):  
Janet Stocks ◽  
Allan Coates ◽  
Andrew Bush
Pneumonia ◽  
2015 ◽  
Vol 6 ◽  
pp. 101 ◽  
Author(s):  
Keith Grimwood ◽  
Anne B Chang

<p class="p1">Each year an estimated 120 million episodes of pneumonia occur in children younger than 5 years of age, resulting in one million deaths globally. Within this age group the lungs are still developing by increasing alveoli numbers and airway dimensions. Pneumonia during this critical developmental period may therefore adversely affect the lung’s structure and function, with increased risk of subsequent chronic lung disease. However, there are few longitudinal studies of pneumonia in otherwise healthy children that extend into adulthood to help address this important question. Birth cohort, longitudinal, case-control and retrospective studies have reported restrictive and obstructive lung function deficits, asthma, bronchiectasis, and chronic obstructive pulmonary disease. In particular, severe hospitalised pneumonia had the greatest risk for long-term sequelae. Most studies, however, were limited by incomplete follow-up, some reliance upon parental recall, risk of diagnostic misclassification, and potential confounders such as nutrition, social deprivation, and pre-existing small airways or lungs. More long-term studies measuring lung function shortly after birth are needed to help disentangle the complex relationships between pneumonia and later chronic lung disease, while also addressing host responses, types of infection, and potential confounding variables. Meanwhile, parents of young children with pneumonia need to be advised about the importance of symptom resolution, post-pneumonia. In addition, paying attention to factors associated with optimising lung growth such as good nutrition, minimising exposure to air pollution, avoiding cigarette smoke, and decreasing the risk of preventable infections through good hygiene and having their children fully vaccinated should be emphasised. Finally, in the developing world and for disadvantaged communities in developed countries, public health policies leading to good quality housing and heating, hygiene, education, and improving socio-economic status are also essential.</p>


2020 ◽  
Vol 19 (6) ◽  
pp. 917-922 ◽  
Author(s):  
Rosemary Carzino ◽  
Katherine B. Frayman ◽  
Louise King ◽  
Suzanna Vidmar ◽  
Sarath Ranganathan

2007 ◽  
Vol 42 (2) ◽  
pp. 107-113 ◽  
Author(s):  
Olivia Williams ◽  
Gabriel Dimitriou ◽  
Simon Hannam ◽  
Gerrard F. Rafferty ◽  
Anne Greenough

2006 ◽  
Vol 41 (3) ◽  
pp. 199-214 ◽  
Author(s):  
Sooky Lum ◽  
Georg Hülskamp ◽  
Peter Merkus ◽  
Eugenio Baraldi ◽  
Ward Hofhuis ◽  
...  

2005 ◽  
Vol 15 (3) ◽  
pp. 256-265 ◽  
Author(s):  
Damien Bonnet ◽  
Achim A. Schmaltz ◽  
Timothy F. Feltes

The respiratory syncytial virus is the most common cause of infection of the lower respiratory tract in infants and young children, and is the leading cause of hospitalisation and death due to viral illness during the first year of life. In otherwise healthy infants, the virus usually causes only mild respiratory illness, but premature babies and infants with chronic lung disease, those with congenitally malformed hearts, or those who are immunodeficient, are at increased risk of serious illness, hospitalisation, and death. Recent infection with the virus is also associated with increased postoperative complications after corrective surgery for congenitally malformed hearts. No effective vaccine is currently available, and treatment is limited to supportive therapy. Prevention in groups deemed to be at high-risk, therefore, is essential. In addition to measures for control of infection, prophylactic immunotherapy is indicated in selected patients. Palivizumab (Synagis®) is a monoclonal antibody indicated for the prevention of serious viral disease of the lower respiratory tract in premature infants, those with chronic lung disease, and those with haemodynamically significant congenital cardiac lesions. Palivizumab is given intramuscularly, usually as a monthly injection during the so-called “season”. In a recent international, randomised, double-blind, placebo-controlled trial in 1,287 children less than or equal to 2 years old with haemodynamically significant congenital cardiac malformations, prophylaxis achieved a relative reduction of 45 per cent in the incidence of antigen-confirmed viral-related hospitalisation, and reduced the duration of hospital stay by 56 per cent. National and international guidelines, therefore, now recommend routine prophylaxis in the first year of life in children with haemodynamically significant congenital cardiac disease.


2015 ◽  
Vol 12 (1) ◽  
pp. 21-26 ◽  
Author(s):  
Cristine E. Berry ◽  
Meilan K. Han ◽  
Bruce Thompson ◽  
Andrew H. Limper ◽  
Fernando J. Martinez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document